Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 7/20 | 0.70 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.70 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.70 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | SGMS2 | Q8NHU3 | 2/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14508840 | 0.90 | FOLH1 (0.66) | SMPD1HDAC8HDAC1HDAC6FOLH1 | |
| SCHEMBL5485830 | 0.89 | SMPD1 (0.62) | SMPD1HDAC8HDAC1HDAC6FOLH1 | |
| SCHEMBL6687833 | 0.88 | HDAC8 (0.73) | SMPD1HDAC8HDAC1HDAC6KDM4E | |
| SCHEMBL1649243 | 0.87 | FOLH1 (0.68) | FOLH1KDM4EALDH1A1POLBL3MBTL1 | |
| SCHEMBL551475 | 0.83 | FOLH1 (0.60) | SMPD1HDAC8HDAC1HDAC6FOLH1 | |
| SCHEMBL131229 | 0.83 | FOLH1 (0.63) | FOLH1KDM4EALDH1A1POLBL3MBTL1 | |
| SCHEMBL6687841 | 0.83 | SMPD1 (0.65) | SMPD1HDAC8HDAC1HDAC6KDM4E | |
| SCHEMBL28591307 | 0.82 | SMPD1 (1.00) | SMPD1HDAC8HDAC1HDAC6KDM4E | |
| SCHEMBL28325672 | 0.82 | SMPD1 (0.90) | SMPD1HDAC8HDAC1HDAC6KDM4E | |
| SCHEMBL4295650 | 0.82 | FOLH1 (0.62) | SMPD1HDAC8HDAC1HDAC6FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | GUILFORD PHARMACEUTICALS INC. | 2004-09-23 | — | — | US | claimed |
| WO-2004078180-A2 | NAALADASE INHIBITORS FOR TREATING OPIOID TOLERANCE | GUILFORD PHARMACEUTICALS INC. (US) | 2004-09-16 | — | — | WO | claimed |
| EP-1292601-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2003-03-19 | — | — | EP | claimed |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | EISAI INC. | 2003-02-20 | — | — | US | claimed |
| WO-2001092274-A2 | NAALADASE INHIBITORS FOR TREATING RETINAL DISORDERS AND GLAUCOMA | GUILFORD PHARMACEUTICALS INC. (US) | 2001-12-06 | — | — | WO | claimed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-7220780-B2 | Naaladase inhibitors for treating retinal disorders and glaucoma | GUILFORD PHARMACEUTICALS INC. (US) | 2007-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186081-A1 | Naaladase inhibitors for treating opioid tolerance | OPRD1, OPRK1, OPRM1 | SMPD1 713/4885HDAC8 1064/4885HDAC1 606/4885 |
| US-20030036534-A1 | Naaladase inhibitors for treating retinal disorders and glaucoma | ALDH1A2, GAA, PDE6A | SMPD1 25/4885HDAC8 1366/4885HDAC1 1579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.